Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Albert

Showing results (361-370 of 437) with videos related to

Pageof 44
Sort By:
Blood Advances|January 8, 2025
Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWPJulia Fekadu-Siebald, Emilia Salzmann-Manrique, Jan Robert Heusel, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2017
Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiencyDaniel Petersheim, Michel J Massaad, Saetbyul Lee, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Bone Marrow Transplantation|October 26, 2010
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programK Hübel, M M Fresen, H Salwender, et al.
Blood|July 24, 2024
Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case seriesSamuele Naviglio, Maria Pia Cicalese, Elizabeth Rivers, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 6, 2022
ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in childrenBianca A W Hoeben, Montserrat Pazos, Enrica Seravalli, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Pageof 44

Showing results (361-370 of 437) with videos related to

Sort By:
Pageof 44
Blood Advances|January 8, 2025
Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWPJulia Fekadu-Siebald, Emilia Salzmann-Manrique, Jan Robert Heusel, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2017
Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiencyDaniel Petersheim, Michel J Massaad, Saetbyul Lee, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Bone Marrow Transplantation|October 26, 2010
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programK Hübel, M M Fresen, H Salwender, et al.
Blood|July 24, 2024
Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case seriesSamuele Naviglio, Maria Pia Cicalese, Elizabeth Rivers, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 6, 2022
ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in childrenBianca A W Hoeben, Montserrat Pazos, Enrica Seravalli, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Pageof 44